Hu Hai, Wang Xiulian, Yu Hui, Wang Zhanli
Inner Mongolia Key Laboratory of Disease-Related Biomarkers, The Second Affiliated Hospital, Baotou Medical College, Baotou, China.
School of Basic Medicine, Baotou Medical College, Baotou, China.
Front Endocrinol (Lausanne). 2025 Jan 9;15:1444940. doi: 10.3389/fendo.2024.1444940. eCollection 2024.
Cardiac hypertrophy is an adaptive response to pressure or volume overload such as hypertension and ischemic heart diseases. Sustained cardiac hypertrophy eventually leads to heart failure. The pathophysiological alterations of hypertrophy are complex, involving both cellular and molecular systems. Understanding the molecular events that inhibit or repress cardiac hypertrophy may help identify novel therapeutic strategies. Increasing evidence has indicated that extracellular vesicle (EV)-derived microRNAs (miRNAs) play a significant role in the development and progression of cardiac hypertrophy. In this review, we briefly review recent advancements in EV research, especially on biogenesis, cargoes and its role in cardiac hypertrophy. We then describe the latest findings regarding EV-derived miRNAs, highlighting their functions and regulatory mechanisms in cardiac hypertrophy. Finally, the potential role of EV-derived miRNAs as targets in the diagnosis and treatment of cardiac hypertrophy will be discussed.
心脏肥大是对压力或容量超负荷(如高血压和缺血性心脏病)的一种适应性反应。持续性心脏肥大最终会导致心力衰竭。肥大的病理生理改变很复杂,涉及细胞和分子系统。了解抑制或抑制心脏肥大的分子事件可能有助于确定新的治疗策略。越来越多的证据表明,细胞外囊泡(EV)衍生的微小RNA(miRNA)在心脏肥大的发生和发展中起重要作用。在本综述中,我们简要回顾了EV研究的最新进展,特别是关于生物发生、货物及其在心脏肥大中的作用。然后,我们描述了关于EV衍生miRNA的最新发现,强调了它们在心脏肥大中的功能和调节机制。最后,将讨论EV衍生miRNA作为心脏肥大诊断和治疗靶点的潜在作用。